No Data
Beijing Science Sun Pharmaceutical (300485.SZ): The subsidiary's application for the listing of the Active Pharmaceutical Ingredient Dapagliflozin has been accepted.
On December 23, the company Beijing Science Sun Pharmaceutical (300485.SZ) announced that its subsidiary, Beijing Sai'er Biopharmaceutical Co., Ltd. (hereinafter referred to as "Sai'er Biopharmaceutical"), has recently received the "Acceptance Notice" for the marketing application of Dapagliflozin Active Pharmaceutical Ingredient issued by the National Medical Products Administration. Dapagliflozin is a new type of oral hypoglycemic agent, originally developed by Bristol-Myers Squibb, which later licensed the intellectual property and Global production and sales rights to AstraZeneca. In 2012, Dapagliflozin was approved by the European EMA for the treatment of type 2 diabetes, becoming the first drug in the SGLT-2 class approved globally; in 2014, it was approved in the USA.
Beijing Science Sun Pharmaceutical (300485.SZ): Change in production license for Beiao Biomedical pharmaceutical.
Gelonghui, November 20th丨Beijing Science Sun Pharmaceutical (300485.SZ) announced that its subsidiary Peking Saier Biological Pharmaceutical Co., Ltd. (hereinafter referred to as "Saier Biological") recently obtained the "Pharmaceutical Production License" issued by the Beijing Municipal Drug Administration. The matters related to the change are: After reviewing the documents and on-site inspection by the bureau, it is agreed that your unit's "Pharmaceutical Production License" located at No. 2 Tengfei Street, Jingjinzhou River Technology Industrial Park, Jizhou District, Tianjin, will add the production scope: "Active Pharmaceutical Ingredient (Dapagliflozin) (for registration and declaration use only)". This addition of the production scope is pending.
Saisheng Pharmaceutical: Report for the third quarter of 2024
Beijing Science Sun Pharmaceutical (300485.SZ): a net loss of 98.1982 million yuan in the first three quarters.
On October 24, GeLongHui reported that Beijing Science Sun Pharmaceutical (300485.SZ) released its third quarter report for 2024. In the first three quarters of 2024, the company achieved revenue of 0.323 billion yuan, a decrease of 18.01% year-on-year; the net income attributable to shareholders of the listed company was a loss of 98.1982 million yuan, a decrease of 149.97% year-on-year; the net income after deducting non-recurring gains and losses was 17.5475 million yuan, a decrease of 21.27% year-on-year; and the basic EPS was -0.20 yuan per share.
Beijing Science Sun Pharmaceutical (300485.SZ): The company's related products have been approved for use in patients with acute ischemic stroke.
Beijing Science Sun Pharmaceutical (300485.SZ) announced that the company has followed the State Food and Drug Administration's "Regarding Sialic Acid Tetrahexoside...
Beijing Science Sun Pharmaceutical (300485.SZ): The company's main business does not currently involve the CXO field.
Saisun Pharmaceutical (300485.SZ) stated on the investor interaction platform on October 11 that the company's main business does not currently involve the CXO field.